SOST and osteoarthritis: These data suggest that the administration of the proteasome inhibitor Bortezomib is unable to protect against surgically induced osteoarthritis pathology, and has no effect on E11 expression in the SCB, but does diminish sclerostin expression in hypertrophic chondrocytes of the articular cartilage.